Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Your Article Summary
See Latest ArticlesSafety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis
Antimicrobial Agents and Chemotherapy, 06/29/09
Spellberg B et al. - Deferasirox was administered for an average of 14 days at 5 to 20 mg/kg of body weight/day. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Acyclovir: a new use for an old drug
Current Opinion in Infectious Diseases, 10/28/09
Drugs for preventing malaria in travellers
Cochrane Reviews, 10/23/09
Comparison of Gentamicin and Mupirocin in the Prevention of Exit-Site Infection and Peritonitis in Peritoneal Dialysis
Advances in Peritoneal Dialysis, 10/21/09
Today in Fungal Infections...keeping you current
Receive free subspecialty "5-minute updates" via email
Hyperbaric oxygen therapy as an anti-infective agent
Expert Review of Anti-infective Therapy, 10/21/09
Ulcerative leg nodules in a transplant recipient
Cleveland Clinic Journal of Medicine, 10/16/09
Oral potassium iodide for the treatment of sporotrichosis
Cochrane Reviews, 10/26/09
Article Search
Sponsor